Aragen is a world leader in accelerating preclinical R&D in NASH and metabolic diseases. We combine our deep experience with in vitro, in vivo, and in silico platforms with our broad expertise in discovery and development of small and large molecules, to help our clients develop drugs that can address this debilitating metabolic disease. We have helped understand the therapeutic efficacy, safety, and mode of action of a variety of drug candidates that target various aspects of NASH, ranging from metabolic dysfunction to inflammation and fibrosis, thereby helping in strategic pipeline decisions. With AAALAC accredited vivariums in California and in India, our scientific team functions as a global extension of your team running fully integrated projects or specific aspects of an R&D project. Let’s collaborate on your NASH project!